MaxCyte, Inc. (MXCT)

MaxCyte's stock has experienced a significant decline over the past six months. Analyst ratings have fluctuated, with some downgrades followed by an upgrade. The company reported its Q3 2025 earnings, missing EPS and revenue estimates. MaxCyte provided initial 2025 revenue guidance and announced a planned CFO transition. Several hedge funds and institutional investors have adjusted their positions in the company.

MaxCyte does not expect significant seasonality in its forecast for the year. Demand for MaxCyte's electroporation technology is driven by innovation and complexity in cell therapy development. The company's strategy focuses on expanding its Strategic Platform Licenses (SPLs).

MaxCyte, Inc. is a clinical-stage cell therapy platform company in the biotechnology industry, specializing in flow electroporation technology. Its core business revolves around the ExPERT™ platform, supporting the cell therapy market. MaxCyte offers the ExPERT family of instruments, disposable processing assemblies, and accessories, licensing and selling its technology to developers of cell therapies, pharmaceutical, and biotechnology companies.

MaxCyte, Inc. discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company is headquartered in Rockville, Maryland, and has a global customer base.

Information specifically detailing MaxCyte's brand reputation is not explicitly available. Analyst ratings provide some insight into financial community perception. MaxCyte has a consensus "Hold" rating from brokerages.

MaxCyte, Inc. has 236 institutional owners and shareholders holding a total of 79,583,950 shares, representing 68.81% of the company's stock. Individual insiders own 1.41% of the shares, totaling 1,507,037 shares. Insider sentiment for MaxCyte, Inc. is positive.